GC Cell（A144510）株式概要GCセル・コーポレーションは細胞治療製品を開発している。 詳細A144510 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去5年間で収益は年間79.4%減少しました。 すべてのリスクチェックを見るA144510 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩21.20k54.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-273b236b2016201920222025202620282031Revenue ₩206.8bEarnings ₩37.6bAdvancedSet Fair ValueView all narrativesGC Cell Corporation 競合他社Dx & VxSymbol: KOSDAQ:A180400Market cap: ₩328.3bAnterogen.Co.LtdSymbol: KOSDAQ:A065660Market cap: ₩305.7bTiumBioSymbol: KOSDAQ:A321550Market cap: ₩234.0bHansBiomedSymbol: KOSDAQ:A042520Market cap: ₩410.7b価格と性能株価の高値、安値、推移の概要GC Cell過去の株価現在の株価₩21,200.0052週高値₩28,450.0052週安値₩18,210.00ベータ0.641ヶ月の変化-15.20%3ヶ月変化-12.94%1年変化5.47%3年間の変化-54.01%5年間の変化-78.76%IPOからの変化-55.93%最新ニュースReported Earnings • Mar 20Full year 2025 earnings released: ₩18,158 loss per share (vs ₩4,918 loss in FY 2024)Full year 2025 results: ₩18,158 loss per share (further deteriorated from ₩4,918 loss in FY 2024). Revenue: ₩165.5b (down 5.1% from FY 2024). Net loss: ₩272.9b (loss widened 269% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.お知らせ • Feb 06GC Cell Corporation, Annual General Meeting, Mar 24, 2026GC Cell Corporation, Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South KoreaNew Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Earnings have declined by 62% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).分析記事 • Nov 05GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryThe GC Cell Corporation ( KOSDAQ:144510 ) share price has done very well over the last month, posting an excellent gain...分析記事 • Oct 31GC Cell (KOSDAQ:144510) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Apr 09Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% PlummetUnfortunately for some shareholders, the GC Cell Corporation ( KOSDAQ:144510 ) share price has dived 26% in the last...最新情報をもっと見るRecent updatesReported Earnings • Mar 20Full year 2025 earnings released: ₩18,158 loss per share (vs ₩4,918 loss in FY 2024)Full year 2025 results: ₩18,158 loss per share (further deteriorated from ₩4,918 loss in FY 2024). Revenue: ₩165.5b (down 5.1% from FY 2024). Net loss: ₩272.9b (loss widened 269% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.お知らせ • Feb 06GC Cell Corporation, Annual General Meeting, Mar 24, 2026GC Cell Corporation, Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South KoreaNew Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Earnings have declined by 62% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).分析記事 • Nov 05GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryThe GC Cell Corporation ( KOSDAQ:144510 ) share price has done very well over the last month, posting an excellent gain...分析記事 • Oct 31GC Cell (KOSDAQ:144510) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Apr 09Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% PlummetUnfortunately for some shareholders, the GC Cell Corporation ( KOSDAQ:144510 ) share price has dived 26% in the last...Reported Earnings • Mar 21Full year 2024 earnings released: ₩4,918 loss per share (vs ₩12.00 loss in FY 2023)Full year 2024 results: ₩4,918 loss per share (further deteriorated from ₩12.00 loss in FY 2023). Revenue: ₩174.5b (down 7.0% from FY 2023). Net loss: ₩73.9b (loss widened ₩73.7b from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.お知らせ • Mar 13GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, A Promising T-Cell Lymphoma CD5 CAR-NK TherapyGC Cell announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB-205), a novel CD5 CAR-NK cell therapy. This "first patient dosing" marks a critical milestone in the company's collaboration with its ex-APAC partner Artiva Biotherapeutics, as company advance the development of this innovative treatment targeting relapsed or refractory NK and T-cell malignancies. With GCC2005, GC Cell is striving to fulfill a significant unmet need in oncology. T-cell lymphomas, which often arise in extranodal lymphoid tissues, are highly aggressive and generally exhibit a poorer prognosis than their B-cell counterparts with limited treatment options. Aimed at expanding possibilities for NK-cell therapies, GCC2005 is an allogeneic cell therapy product manufactured using umbilical cord blood–derived NK cells. Engineered to target the CD5 marker—which is highly expressed on T-cell lymphomas—GCC2005 co-expresses a chimeric antigen receptor (CAR) alongside interleukin-15 (IL-15). This dual expression is designed to enhance the persistence and anti-tumor efficacy of NK cells—effectively addressing a common limitation of conventional NK-cell therapies. The ongoing Phase 1 trial (ClinicalTrials.gov Identifier: NCT06699771) will enroll up to approximately 48 patients diagnosed with relapsed or refractory NK and T-cell malignancies. The primary objectives of the study are to evaluate the safety and tolerability of GCC2005, the maximum tolerated dose (MTD), and the recommended Phase 2 dose (RP2D). Preclinical efficacy data presented last year at the American Association for Cancer Research (AACR) and the T Cell Lymphoma Forum (TCLF) highlighted GCC2005's potent ability to kill tumor cells and improve in vivo persistence. These promising results have bolstered expectations that GCC2005 could become a global first-in-class therapeutic option for T-cell lymphoma. In recognition of its innovative potential, GCC2005 has also been selected by a Korea Drug Development Fund program aimed at promoting global market entry and strategic partnerships in drug development.お知らせ • Feb 12GC Cell Corporation, Annual General Meeting, Mar 25, 2025GC Cell Corporation, Annual General Meeting, Mar 25, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea分析記事 • Dec 01The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%The GC Cell Corporation ( KOSDAQ:144510 ) share price has fared very poorly over the last month, falling by a...分析記事 • Oct 14Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share PriceGC Cell Corporation's ( KOSDAQ:144510 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...分析記事 • Sep 08Is GC Cell (KOSDAQ:144510) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Mar 22Full year 2023 earnings released: ₩12.00 loss per share (vs ₩1,767 profit in FY 2022)Full year 2023 results: ₩12.00 loss per share (down from ₩1,767 profit in FY 2022). Revenue: ₩187.5b (down 21% from FY 2022). Net loss: ₩174.0m (down 101% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.お知らせ • Jan 09GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI PlatformGC Cell announce the approval from both the Australian Human Research Ethics Committee (HREC) and the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1 Investigational New Drug (IND) trial for its AB-201 cancer treatment, a HER2 targeted chimeric antigen receptor-natural killer (CAR-NK) cell therapy that shows great promise. Additionally, GC Cell is excited to reveal a strategic partnership with Lunit, the medical AI leader, to enhance precision and clinical intelligence of AB-201's efficacy evaluation by applying its advanced AI technology, in addition to traditional Immunohistochemistry (IHC) based assessments. After participating in the US White House's Cancer Moonshot initiative this past October, both accomplishments represent major milestones in GC Cell's efforts to revolutionize immunotherapy-based cancer treatment while harnessing AI and digital transformation to fight cancer. AB-201, a novel CAR-NK cell therapy targeting solid tumors, represents a breakthrough in cancer immunotherapy, capable of killing malignant cells. While existing NK cell treatments typically dissipate within a few weeks, AB-201 has demonstrated persistence for over three months in preclinical studies, highlighting its potential in managing long-term, advanced cancers. A multi-country study, the Phase 1 trial will evaluate safety and efficacy in 48 patients with HER2-overexpressing breast, gastric, and gastroesophageal junction cancers. GC Cell holds exclusive rights to AB-201 in the Asia Pacific region, while ex-Asia-Pacific rights were licensed to Artiva Biotherapeutics Inc. in an exclusive partnership. A recent McKinsey report found that AI has the potential to increase the value of the pharmaceutical R&D industry by six to eleven billion US dollars. Employing the technology, GC Cell anticipates that AI-driven imaging can analyze vast amounts of data with a high degree of precision and consistency while reducing variability by individual interpretation. This leads to a more accurate assessment of HER2 expression levels, which is vital for appropriate treatment decisions. With such quantitative analysis, AI can help standardize the assessment of cancer target expression across different laboratories and geographical locations. This standardization is essential for multicenter clinical trials and for ensuring that patients receive consistent care regardless of where they are treated. It's a pivotal step in GC Cell's journey towards a digital future, aligning with the broader healthcare industry's shift towards technology-enhanced solutions. AB-201 is an allogeneic HER2-targeted chimeric antigen receptor NK (CAR-NK) cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing. A novel, high affinity anti-HER2 antibody converted to scFv structure confers highly specific tumor targeting and is coupled with a unique costimulatory structure and IL-15 expression for enhanced activity and persistence. AB-201 has demonstrated potent anti-tumor activity in multiple preclinical HER2-positive tumor model systems. The underlying NK cell is derived from umbilical cord blood donors preselected for advantageous attributes including the high affinity variant of the CD16 receptor and a KIR-B haplotype. AB-201 cell products maintain high expression of CD16, as well as other activating innate cell tumor engaging receptors, enabling the potential for dual targeting therapeutic approaches via monoclonal antibody combinations. The resulting CAR-NK is manufactured at very large scale and cryopreserved in infusion-ready media to enable repeat clinical administrations in the outpatient setting. GC Cell holds exclusive rights to AB-201 in the Asia-Pacific region, while ex-Asia-Pacific rights were licensed to Artiva Biotherapeutics Inc. in an exclusive partnership. The U.S. Food and Drug Administration previously cleared Artiva's investigational new drug (IND) application for AB-201 in 2022.Upcoming Dividend • Dec 20Upcoming dividend of ₩350 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.7%).New Risk • Jul 07New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. The company is paying a dividend despite being loss-making. Dividend yield: 1.0% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,767 (vs ₩2,785 in FY 2021)Full year 2022 results: EPS: ₩1,767 (down from ₩2,785 in FY 2021). Revenue: ₩236.1b (up 40% from FY 2021). Net income: ₩26.5b (down 16% from FY 2021). Profit margin: 11% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩70,000, the stock trades at a trailing P/E ratio of 20.6x. Average forward P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years.Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩74,000, the stock trades at a trailing P/E ratio of 75.9x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 68% over the past three years.Upcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 31 March 2022. Payout ratio is a comfortable 6.9% and this is well supported by cash flows. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).分析記事 • Mar 19We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are ConservativeWhen companies post strong earnings, the stock generally performs well, just like Green Cross Lab Cell Corporation's...Reported Earnings • Mar 18Full year 2020 earnings released: EPS ₩394 (vs ₩216 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩85.6b (up 48% from FY 2019). Net income: ₩4.16b (up ₩6.44b from FY 2019). Profit margin: 4.9% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.分析記事 • Feb 22We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • Feb 10Green Cross Lab Cell Corporation, Annual General Meeting, Mar 24, 2021Green Cross Lab Cell Corporation, Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Jan 27New 90-day high: ₩124,500The company is up 160% from its price of ₩47,850 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period.分析記事 • Jan 18Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...Is New 90 Day High Low • Dec 22New 90-day high: ₩86,000The company is up 73% from its price of ₩49,800 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period.Upcoming Dividend • Dec 22Upcoming Dividend of ₩25.00 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of December. The trailing yield of 0.03% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%).分析記事 • Dec 14Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...Is New 90 Day High Low • Nov 23New 90-day high: ₩59,100The company is up 4.0% from its price of ₩57,000 on 25 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: ₩45,550The company is down 15% from its price of ₩53,800 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩49,800The company is down 13% from its price of ₩57,200 on 25 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.株主還元A144510KR BiotechsKR 市場7D-2.5%0.3%4.6%1Y5.5%33.1%186.7%株主還元を見る業界別リターン: A144510過去 1 年間で33.1 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A144510は、過去 1 年間で186.7 % のリターンを上げたKR市場を下回りました。価格変動Is A144510's price volatile compared to industry and market?A144510 volatilityA144510 Average Weekly Movement9.4%Biotechs Industry Average Movement11.5%Market Average Movement9.4%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%安定した株価: A144510 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A144510の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2011698Jai-Wang Kimwww.gccell.comGCセル・コーポレーションは細胞治療製品を開発。細胞バンク、検体検査、臨床試験、バイオ物流サービスも提供。主力製品はImmuncell-LC。株式会社ジーシーセルはルーカス・バイオメディカル株式会社と細胞治療開発に関する戦略的提携を結んでいる。同社の前身はグリーンクロスラボセル株式会社であり、2021年11月にGCセル株式会社に社名変更した。GC Cell Corporationは2011年に設立され、韓国の龍仁市に拠点を置いている。もっと見るGC Cell Corporation 基礎のまとめGC Cell の収益と売上を時価総額と比較するとどうか。A144510 基礎統計学時価総額₩318.58b収益（TTM）-₩272.86b売上高(TTM)₩165.52b1.9xP/Sレシオ-1.2xPER（株価収益率A144510 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A144510 損益計算書（TTM）収益₩165.52b売上原価₩136.55b売上総利益₩28.97bその他の費用₩301.83b収益-₩272.86b直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-18.16kグロス・マージン17.50%純利益率-164.85%有利子負債／自己資本比率27.1%A144510 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 07:31終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GC Cell Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Jinhee KwakEugene Investment & Securities Co Ltd.Seung-Ho LeeNH Investment & Securities Co., Ltd.
Reported Earnings • Mar 20Full year 2025 earnings released: ₩18,158 loss per share (vs ₩4,918 loss in FY 2024)Full year 2025 results: ₩18,158 loss per share (further deteriorated from ₩4,918 loss in FY 2024). Revenue: ₩165.5b (down 5.1% from FY 2024). Net loss: ₩272.9b (loss widened 269% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 06GC Cell Corporation, Annual General Meeting, Mar 24, 2026GC Cell Corporation, Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Earnings have declined by 62% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
分析記事 • Nov 05GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryThe GC Cell Corporation ( KOSDAQ:144510 ) share price has done very well over the last month, posting an excellent gain...
分析記事 • Oct 31GC Cell (KOSDAQ:144510) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Apr 09Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% PlummetUnfortunately for some shareholders, the GC Cell Corporation ( KOSDAQ:144510 ) share price has dived 26% in the last...
Reported Earnings • Mar 20Full year 2025 earnings released: ₩18,158 loss per share (vs ₩4,918 loss in FY 2024)Full year 2025 results: ₩18,158 loss per share (further deteriorated from ₩4,918 loss in FY 2024). Revenue: ₩165.5b (down 5.1% from FY 2024). Net loss: ₩272.9b (loss widened 269% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 06GC Cell Corporation, Annual General Meeting, Mar 24, 2026GC Cell Corporation, Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Earnings have declined by 62% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
分析記事 • Nov 05GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryThe GC Cell Corporation ( KOSDAQ:144510 ) share price has done very well over the last month, posting an excellent gain...
分析記事 • Oct 31GC Cell (KOSDAQ:144510) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Apr 09Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% PlummetUnfortunately for some shareholders, the GC Cell Corporation ( KOSDAQ:144510 ) share price has dived 26% in the last...
Reported Earnings • Mar 21Full year 2024 earnings released: ₩4,918 loss per share (vs ₩12.00 loss in FY 2023)Full year 2024 results: ₩4,918 loss per share (further deteriorated from ₩12.00 loss in FY 2023). Revenue: ₩174.5b (down 7.0% from FY 2023). Net loss: ₩73.9b (loss widened ₩73.7b from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 13GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, A Promising T-Cell Lymphoma CD5 CAR-NK TherapyGC Cell announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB-205), a novel CD5 CAR-NK cell therapy. This "first patient dosing" marks a critical milestone in the company's collaboration with its ex-APAC partner Artiva Biotherapeutics, as company advance the development of this innovative treatment targeting relapsed or refractory NK and T-cell malignancies. With GCC2005, GC Cell is striving to fulfill a significant unmet need in oncology. T-cell lymphomas, which often arise in extranodal lymphoid tissues, are highly aggressive and generally exhibit a poorer prognosis than their B-cell counterparts with limited treatment options. Aimed at expanding possibilities for NK-cell therapies, GCC2005 is an allogeneic cell therapy product manufactured using umbilical cord blood–derived NK cells. Engineered to target the CD5 marker—which is highly expressed on T-cell lymphomas—GCC2005 co-expresses a chimeric antigen receptor (CAR) alongside interleukin-15 (IL-15). This dual expression is designed to enhance the persistence and anti-tumor efficacy of NK cells—effectively addressing a common limitation of conventional NK-cell therapies. The ongoing Phase 1 trial (ClinicalTrials.gov Identifier: NCT06699771) will enroll up to approximately 48 patients diagnosed with relapsed or refractory NK and T-cell malignancies. The primary objectives of the study are to evaluate the safety and tolerability of GCC2005, the maximum tolerated dose (MTD), and the recommended Phase 2 dose (RP2D). Preclinical efficacy data presented last year at the American Association for Cancer Research (AACR) and the T Cell Lymphoma Forum (TCLF) highlighted GCC2005's potent ability to kill tumor cells and improve in vivo persistence. These promising results have bolstered expectations that GCC2005 could become a global first-in-class therapeutic option for T-cell lymphoma. In recognition of its innovative potential, GCC2005 has also been selected by a Korea Drug Development Fund program aimed at promoting global market entry and strategic partnerships in drug development.
お知らせ • Feb 12GC Cell Corporation, Annual General Meeting, Mar 25, 2025GC Cell Corporation, Annual General Meeting, Mar 25, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea
分析記事 • Dec 01The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%The GC Cell Corporation ( KOSDAQ:144510 ) share price has fared very poorly over the last month, falling by a...
分析記事 • Oct 14Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share PriceGC Cell Corporation's ( KOSDAQ:144510 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...
分析記事 • Sep 08Is GC Cell (KOSDAQ:144510) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Mar 22Full year 2023 earnings released: ₩12.00 loss per share (vs ₩1,767 profit in FY 2022)Full year 2023 results: ₩12.00 loss per share (down from ₩1,767 profit in FY 2022). Revenue: ₩187.5b (down 21% from FY 2022). Net loss: ₩174.0m (down 101% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 09GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI PlatformGC Cell announce the approval from both the Australian Human Research Ethics Committee (HREC) and the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1 Investigational New Drug (IND) trial for its AB-201 cancer treatment, a HER2 targeted chimeric antigen receptor-natural killer (CAR-NK) cell therapy that shows great promise. Additionally, GC Cell is excited to reveal a strategic partnership with Lunit, the medical AI leader, to enhance precision and clinical intelligence of AB-201's efficacy evaluation by applying its advanced AI technology, in addition to traditional Immunohistochemistry (IHC) based assessments. After participating in the US White House's Cancer Moonshot initiative this past October, both accomplishments represent major milestones in GC Cell's efforts to revolutionize immunotherapy-based cancer treatment while harnessing AI and digital transformation to fight cancer. AB-201, a novel CAR-NK cell therapy targeting solid tumors, represents a breakthrough in cancer immunotherapy, capable of killing malignant cells. While existing NK cell treatments typically dissipate within a few weeks, AB-201 has demonstrated persistence for over three months in preclinical studies, highlighting its potential in managing long-term, advanced cancers. A multi-country study, the Phase 1 trial will evaluate safety and efficacy in 48 patients with HER2-overexpressing breast, gastric, and gastroesophageal junction cancers. GC Cell holds exclusive rights to AB-201 in the Asia Pacific region, while ex-Asia-Pacific rights were licensed to Artiva Biotherapeutics Inc. in an exclusive partnership. A recent McKinsey report found that AI has the potential to increase the value of the pharmaceutical R&D industry by six to eleven billion US dollars. Employing the technology, GC Cell anticipates that AI-driven imaging can analyze vast amounts of data with a high degree of precision and consistency while reducing variability by individual interpretation. This leads to a more accurate assessment of HER2 expression levels, which is vital for appropriate treatment decisions. With such quantitative analysis, AI can help standardize the assessment of cancer target expression across different laboratories and geographical locations. This standardization is essential for multicenter clinical trials and for ensuring that patients receive consistent care regardless of where they are treated. It's a pivotal step in GC Cell's journey towards a digital future, aligning with the broader healthcare industry's shift towards technology-enhanced solutions. AB-201 is an allogeneic HER2-targeted chimeric antigen receptor NK (CAR-NK) cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing. A novel, high affinity anti-HER2 antibody converted to scFv structure confers highly specific tumor targeting and is coupled with a unique costimulatory structure and IL-15 expression for enhanced activity and persistence. AB-201 has demonstrated potent anti-tumor activity in multiple preclinical HER2-positive tumor model systems. The underlying NK cell is derived from umbilical cord blood donors preselected for advantageous attributes including the high affinity variant of the CD16 receptor and a KIR-B haplotype. AB-201 cell products maintain high expression of CD16, as well as other activating innate cell tumor engaging receptors, enabling the potential for dual targeting therapeutic approaches via monoclonal antibody combinations. The resulting CAR-NK is manufactured at very large scale and cryopreserved in infusion-ready media to enable repeat clinical administrations in the outpatient setting. GC Cell holds exclusive rights to AB-201 in the Asia-Pacific region, while ex-Asia-Pacific rights were licensed to Artiva Biotherapeutics Inc. in an exclusive partnership. The U.S. Food and Drug Administration previously cleared Artiva's investigational new drug (IND) application for AB-201 in 2022.
Upcoming Dividend • Dec 20Upcoming dividend of ₩350 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.7%).
New Risk • Jul 07New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. The company is paying a dividend despite being loss-making. Dividend yield: 1.0% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,767 (vs ₩2,785 in FY 2021)Full year 2022 results: EPS: ₩1,767 (down from ₩2,785 in FY 2021). Revenue: ₩236.1b (up 40% from FY 2021). Net income: ₩26.5b (down 16% from FY 2021). Profit margin: 11% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩70,000, the stock trades at a trailing P/E ratio of 20.6x. Average forward P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years.
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩74,000, the stock trades at a trailing P/E ratio of 75.9x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 68% over the past three years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 31 March 2022. Payout ratio is a comfortable 6.9% and this is well supported by cash flows. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).
分析記事 • Mar 19We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are ConservativeWhen companies post strong earnings, the stock generally performs well, just like Green Cross Lab Cell Corporation's...
Reported Earnings • Mar 18Full year 2020 earnings released: EPS ₩394 (vs ₩216 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩85.6b (up 48% from FY 2019). Net income: ₩4.16b (up ₩6.44b from FY 2019). Profit margin: 4.9% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.
分析記事 • Feb 22We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • Feb 10Green Cross Lab Cell Corporation, Annual General Meeting, Mar 24, 2021Green Cross Lab Cell Corporation, Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Jan 27New 90-day high: ₩124,500The company is up 160% from its price of ₩47,850 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period.
分析記事 • Jan 18Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Is New 90 Day High Low • Dec 22New 90-day high: ₩86,000The company is up 73% from its price of ₩49,800 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period.
Upcoming Dividend • Dec 22Upcoming Dividend of ₩25.00 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of December. The trailing yield of 0.03% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%).
分析記事 • Dec 14Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
Is New 90 Day High Low • Nov 23New 90-day high: ₩59,100The company is up 4.0% from its price of ₩57,000 on 25 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: ₩45,550The company is down 15% from its price of ₩53,800 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩49,800The company is down 13% from its price of ₩57,200 on 25 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
